Table 2.
Baseline to 14-month Post-Course Professional Self-Efficacy Outcomes (Level 4 self-assessment of competence in practice)
| Professional Self- Efficacy Subscale |
Data Collection Time Point |
MD (n=12) |
RN (n=17) |
GC (n=23) |
Total (n=52) |
p values main effect/ Interaction ** |
|---|---|---|---|---|---|---|
| Mean* (SD) | Mean* (SD) |
Mean* (SD) |
Mean (SD) | |||
| Genetics/Oncology | Baseline | 4.11 (.57) | 3.26 (.96) | 4.11 (.61) | 3.82 (.84) | <.001/ .002 |
| Post Phase 2 | 4.78 (.19) | 4.40 (.59) | 4.77 (.32) | 4.64 (.45) | ||
| Post Phase 3 | 4.87 (.22) | 4.67 (.37) | 4.82 (.18) | 4.78 (.28) | ||
| Hereditary Cancer Risk Assessment |
Baseline | 3.21 (.85) | 2.24 (1.15) | 3.84 (.67) | 3.17 (1.14) | <.001/ .001 |
| Post Phase 2 | 4.46 (.29) | 4.00 (.61) | 4.74 (.34) | 4.43 (.55) | ||
| Post Phase 3 | 4.48 (.35) | 4.16 (.68) | 4.75 (.21) | 4.50 (.52) | ||
| Testing Strategy/ Test Interpretation |
Baseline | 3.83 (.96) | 2.93 (1.18) | 4.46 (.49) | 3.81 (1.10) | <.001/ <.001 |
| Post Phase 2 | 4.68 (.32) | 4.19 (.75) | 4.91 (.20) | 4.62 (.57) | ||
| Post Phase 3 | 4.70 (.31) | 4.61 (.42) | 4.87 (.24) | 4.75 (.34) | ||
| Risk Management | Baseline | 3.53 (.92) | 2.63 (1.16) | 3.34 (.94) | 3.13 (1.06) | <.001/ .120 |
| Post Phase 2 | 4.53 (.55) | 4.31 (.65) | 4.41 (.44) | 4.40 (.54) | ||
| Post Phase 3 | 4.53 (.65) | 4.28 (.70) | 4.51 (.27) | 4.43 (.53) | ||
| ELSI/Counseling Issues |
Baseline | 3.22 (1.06) | 3.09 (1.09) | 3.83 (.71) | 3.46 (.97) | <.001/ .095 |
| Post Phase 2 | 4.17 (.54) | 4.17 (.56) | 4.64 (.37) | 4.39 (.52) | ||
| Post Phase 3 | 4.44 (.45) | 4.54 (.46) | 4.63 (.37) | 4.56 (.42) | ||
| Research Collaboration |
Baseline | 2.70 (1.20) | 2.38 (1.32) | 3.03 (1.23) | 2.74 (1.26) | <.001/ .232 |
| Post Phase 2 | 4.07 (.68) | 3.84 (.88) | 3.97 (.79) | 3.95 (.79) | ||
| Post Phase 3 | 3.78 (.85) | 3.83 (1.12) | 3.98 (.78) | 3.89 (.91) | ||
| Overall Professional Self-Efficacy Score |
Baseline | 3.43 (.65) | 2.76 (.99) | 3.77 (.60) | 3.35 (.88) | <.001/ .003 |
| Post Phase 2 | 4.45 (.30) | 4.13 (.59) | 4.58 (.30) | 4.409 (.46) | ||
| Post Phase 3 | 4.47 (.28) | 4.33 (.51) | 4.59 (.19) | 4.48 (.36) | ||
NOTE: Scores based on Likert scale ratings from 0 = No Experience/Can’t Assess to 5 = Very Confident
*
Mean baseline to post Phase 2 and post Phase 3 self-efficacy scores were significantly increased by practice discipline overall and for all six subscales (p ≤ .05). By-discipline mean scores increased from Phase 2 to Phase 3 overall and in four of six subscales.
**
Interaction effect (differences between disciplines over time)